Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $49,511.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,100 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $45.01, for a total value of $49,511.00. Following the completion of the sale, the director now directly owns 318,652 shares of the company’s stock, valued at approximately $14,342,526.52. This trade represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Pro-Dex Stock Performance

Shares of PDEX stock opened at $34.34 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The stock has a 50-day moving average of $47.15 and a 200-day moving average of $34.86. Pro-Dex, Inc. has a one year low of $16.18 and a one year high of $59.60. The stock has a market cap of $111.95 million, a PE ratio of 17.08 and a beta of 0.53.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, sell-side analysts expect that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Hedge Funds Weigh In On Pro-Dex

Several institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares during the period. Renaissance Technologies LLC boosted its position in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after acquiring an additional 900 shares during the last quarter. FMR LLC boosted its position in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares during the last quarter. Bard Associates Inc. boosted its position in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after acquiring an additional 2,031 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on PDEX. Ascendiant Capital Markets upped their price target on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, November 11th. StockNews.com cut Pro-Dex from a “strong-buy” rating to a “buy” rating in a research note on Monday.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.